

July 29, 2026

BSE Surveillance
BSE Limited (Scrip Code: 500124)

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (SEBI Listing Regulation) – Clarification sought by stock exchanges on news item appearing in “Media/Publication”

Ref: Verification - July 28, 2026 - Dr Reddy's Laboratories Ltd vide email dated July 28, 2026

This is with reference to your e-mail dated July 28, 2026, on the captioned subject, seeking clarification from the Company regarding a news article published in Business Standard https://www.business-standard.com/companies/news/dr-reddys-first-in-class-gonorrhoea-drug-gets-thailand-approval-after-us-nod-126072700632_1.html on July 28, 2026 with the heading “**Dr Reddys antibiotic gets Thailand approval six months after US nod**”.

In this connection, we wish to inform that the above captioned news item headline is correct, and the Company hereby clarify that the above said news pertains to the Company's joint press release with Global Antibiotic Research & Development Partnership Foundation (“GARDP”) made on July 27, 2026 titled as “Thai FDA approves NUZOLVENCE® (zofludacin) just six months after US authorization.”

We would also like to inform you that the above-mentioned matter does not constitute a material event or information requiring disclosure under Regulation 30 of the SEBI Listing Regulation.

Please note that the Company, in compliance with Regulation 30 of the SEBI Listing Regulations, makes timely disclosures of all events and information considered material and warrants disclosure under the said Regulations.

This is for your information and records.

Thanking you,

Yours faithfully,
For **Dr. Reddy's Laboratories Limited**

K Randhir Singh
Company Secretary, Compliance Officer and Head-CSR